8.000GBp+6.67%Mkt Cap: 155539 GBpP/E: —Last update: 2026-05-13
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicine…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B3.15
P/S—
EV/EBITDA-1.83
EV/Revenue—
EPS (TTM)-0.01
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-1398.53%
FCF Margin—
Operating CF-783.73K GBp
CapEx (TTM)—
Net Debt/EBITDA-0.22
Net Debt200.73K GBp
Technical
SMA 5010.11 (-20.8%)
SMA 20014.79 (-45.9%)
Beta-0.56
S&P 52W Chg24.23%
Avg Vol (30d)123.24K
Avg Vol (10d)12.14K
Technical Indicators
RSI (14)52.0
MACD-0.1737
MACD Signal-0.2498
MACD Hist.+0.0760
BB Upper8.600 GBp
BB Middle7.781 GBp
BB Lower6.963 GBp
BB Width21.04%
ATR (14)0.8602 GBp
Vol Ratio (20d)1.29x
52W Range
0.950024% of range30.00
52W High30.00 GBp
52W Low0.9500 GBp
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-19.88%
ROA-16.90%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.08
Current Ratio2.80
Quick Ratio0.34
Book Value/Sh0.3020 GBp
Cash/Share0.0120 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMar 27, 2026
Ownership
Shares Out.16.37M
Float11.38M
Insiders1.55%
Institutions0.05%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap155.54K GBp
Enterprise Value1.70M GBp
Revenue (TTM)—
Gross Profit-16.00K GBp
Net Income (TTM)-971.80K GBp
Revenue/Share—
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees7
Last Price8.000 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—